These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 25510439)

  • 1. Total synthesis of the tiacumicin B (lipiarmycin A3/fidaxomicin) aglycone.
    Glaus F; Altmann KH
    Angew Chem Int Ed Engl; 2015 Feb; 54(6):1937-40. PubMed ID: 25510439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Total synthesis of the protected aglycon of fidaxomicin (tiacumicin B, lipiarmycin A3).
    Miyatake-Ondozabal H; Kaufmann E; Gademann K
    Angew Chem Int Ed Engl; 2015 Feb; 54(6):1933-6. PubMed ID: 25431322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Total Synthesis of the Glycosylated Macrolide Antibiotic Fidaxomicin.
    Kaufmann E; Hattori H; Miyatake-Ondozabal H; Gademann K
    Org Lett; 2015 Jul; 17(14):3514-7. PubMed ID: 26125969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enantioselective synthesis of putative lipiarmycin aglycon related to fidaxomicin/tiacumicin B.
    Erb W; Grassot JM; Linder D; Neuville L; Zhu J
    Angew Chem Int Ed Engl; 2015 Feb; 54(6):1929-32. PubMed ID: 25422174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Total Synthesis of Tiacumicin A. Total Synthesis, Relay Synthesis, and Degradation Studies of Fidaxomicin (Tiacumicin B, Lipiarmycin A3).
    Hattori H; Kaufmann E; Miyatake-Ondozabal H; Berg R; Gademann K
    J Org Chem; 2018 Jul; 83(13):7180-7205. PubMed ID: 29590752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Final Demonstration of the Co-Identity of Lipiarmycin A3 and Tiacumicin B (Fidaxomicin) through Single Crystal X-ray Analysis.
    Serra S; Malpezzi L; Bedeschi A; Fuganti C; Fonte P
    Antibiotics (Basel); 2017 Feb; 6(1):. PubMed ID: 28208717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis of a Tiacumicin B Protected Aglycone.
    Jeanne-Julien L; Masson G; Astier E; Genta-Jouve G; Servajean V; Beau JM; Norsikian S; Roulland E
    Org Lett; 2017 Aug; 19(15):4006-4009. PubMed ID: 28723103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Total Synthesis of Tiacumicin B: Implementing Hydrogen Bond Directed Acceptor Delivery for Highly Selective β-Glycosylations.
    Norsikian S; Tresse C; François-Eude M; Jeanne-Julien L; Masson G; Servajean V; Genta-Jouve G; Beau JM; Roulland E
    Angew Chem Int Ed Engl; 2020 Apr; 59(16):6612-6616. PubMed ID: 32003915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Total Synthesis of Tiacumicin B: Study of the Challenging β-Selective Glycosylations*.
    Tresse C; François-Heude M; Servajean V; Ravinder R; Lesieur C; Geiben L; Jeanne-Julien L; Steinmetz V; Retailleau P; Roulland E; Beau JM; Norsikian S
    Chemistry; 2021 Mar; 27(16):5230-5239. PubMed ID: 33433914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Co-identity of Lipiarmycin A3 and Tiacumicin B.
    Bedeschi A; Fonte P; Fronza G; Fuganti C; Serra S
    Nat Prod Commun; 2016 May; 11(5):569-72. PubMed ID: 27319118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of a sugar-O-methyltransferase TiaS5 affords new Tiacumicin analogues with improved antibacterial properties and reveals substrate promiscuity.
    Niu S; Hu T; Li S; Xiao Y; Ma L; Zhang G; Zhang H; Yang X; Ju J; Zhang C
    Chembiochem; 2011 Jul; 12(11):1740-8. PubMed ID: 21633995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fidaxomicin for the treatment of Clostridium difficile infections.
    Whitman CB; Czosnowski QA
    Ann Pharmacother; 2012 Feb; 46(2):219-28. PubMed ID: 22318930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile.
    Swanson RN; Hardy DJ; Shipkowitz NL; Hanson CW; Ramer NC; Fernandes PB; Clement JJ
    Antimicrob Agents Chemother; 1991 Jun; 35(6):1108-11. PubMed ID: 1929250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The co-identity of lipiarmycin A3 and tiacumicin B.
    Bedeschi A; Fonte P; Fronza G; Fuganti C; Serra S
    Nat Prod Commun; 2014 Feb; 9(2):237-40. PubMed ID: 24689300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A convergent approach toward fidaxomicin: Syntheses of the fully glycosylated northern and southern fragments.
    Hollibaugh R; Yu X; De Brabander JK
    Tetrahedron; 2020 Dec; 79(4):. PubMed ID: 33191957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections.
    Lancaster JW; Matthews SJ
    Clin Ther; 2012 Jan; 34(1):1-13. PubMed ID: 22284993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tiacumicin Congeners with Improved Antibacterial Activity from a Halogenase-Inactivated Mutant.
    Zhang H; Tian X; Pu X; Zhang Q; Zhang W; Zhang C
    J Nat Prod; 2018 May; 81(5):1219-1224. PubMed ID: 29676573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of the Construction of the Tiacumicin B Aglycone.
    Jeanne-Julien L; Masson G; Astier E; Genta-Jouve G; Servajean V; Beau JM; Norsikian S; Roulland E
    J Org Chem; 2018 Jan; 83(2):921-929. PubMed ID: 29260550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From natural product to marketed drug: the tiacumicin odyssey.
    Erb W; Zhu J
    Nat Prod Rep; 2013 Jan; 30(1):161-74. PubMed ID: 23111588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fidaxomicin: a macrocyclic antibiotic for the management of Clostridium difficile infection.
    Sullivan KM; Spooner LM
    Ann Pharmacother; 2010 Feb; 44(2):352-9. PubMed ID: 20071495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.